Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M1DG
|
|||
| Former ID |
DIB005731
|
|||
| Drug Name |
RTL-1000
|
|||
| Synonyms |
VG-1000; VGI-303; Recombinant t-cell ligand (multiple sclerosis), Artielle
Click to Show/Hide
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Phase 1 | [1] | |
| Company |
Artielle immunotherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cells (T-cells) | Target Info | Binder | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00411723) Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.